Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.

导出 LinkOut

翻译打印收藏纠错

第一作者： Maria A,Pabón

第一单位： Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

作者： Maria A,Pabón ^[1] ; Jonathan W,Cunningham ^[1] ; Brian L,Claggett ^[1] ; Milton,Packer ^[2] ; Michael,Zile ^[3] ; Marc A,Pfeffer ^[1] ; Martin,Lefkowitz ^[4] ; Victor,Shi ^[4] ; Adel,Rizkala ^[4] ; John J V,McMurray ^[5] ; Scott D,Solomon ^[1] ; Muthiah,Vaduganathan ^[1]

作者单位： Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ^[1] Baylor University Medical Center, Dallas, TX, USA. ^[2] RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC, USA. ^[3] Novartis, East Hanover, Hanover, NJ, USA. ^[4] BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. ^[5]

关键词 Clinical trials Heart failure with preserved ejection fraction Natriuretic peptides

主题词血管紧张素受体拮抗剂(Angiotensin Receptor Antagonists);联苯化合物(Biphenyl Compounds);心力衰竭(Heart Failure);人类(Humans);促尿钠排泄肽类(Natriuretic Peptides);每搏输出量(Stroke Volume);血管舒张药(Vasodilator Agents)

DOI 10.1002/ejhf.2439

PMID 35080787

发布时间 2022-09-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交